Article
BRAF mutations in thyroid cancer.
Current opinion in oncology - 1 Jan 2022
Scheffel Rafael Selbach, Dora Jose Miguel, Maia Ana Luiza
Abstract excerpt
PURPOSE OF REVIEW: Activating mutations in the mitogen-activated protein kinase (MAPK) pathway play an important role in papillary (PTC) and anaplastic (ATC) thyroid cancer. The aim of this review is to discuss the impact of BRAF mutations on clinical features and treatment of patients with thyroid cancer. RECENT FINDINGS: Despite the unfavorable course associated with PTCs harboring BRAF V600E mutation, its...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
